Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel in First-line Biliary Tract Cancer
NCT07668453Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in biliary tract cancer (BTC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07668453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668453.